Table 1.

Main clinical trials associating ERCC1 function with response to platinum-based chemotherapy in NSCLC patients.

Author	N	Evaluation	Method of analysis	Conclusion
Olaussen et al. [29]	761	Retrospective	ERCC1 IHC expression	ERCC1 negative tumours derive benefit from cisplatin-based chemotherapy
Zhou et al. [50]	128	Retrospective	RT-PCR for ERCC1 polymorphisms (C8092A)	Increased number of variant ERCC1 alleles associated with decreased overall survival
Isla et al. [18]	62	Retrospective	RT-PCR for ERCC1 SNPs in mRNA from peripheral blood lymphocytes	Patients bearing the homozygous 118C allele have a significantly better survival
Rosell et al. [32–34]	100	Retrospective	RT-PCR for ERCC1 mRNA	Low ERCC1 mRNA levels associated with better median survival
Ceppi et al. [8]	70	Retrospective	RT-PCR for ERCC1 mRNA	Low ERCC1 mRNA levels associated with better median survival
Azuma et al. [2]	67	Retrospective	ERCC1 IHC expression	ERCC1 ICH expression is prognostic for survival after cisplatin-based chemotherapy
Bepler et al. [5]	54	Prospective phase II	RT-PCR for ERCC1 gene	ERCC1 expression predictive of tumor response
Simon G et al. [40]	60	Prospective phase II	RT-PCR for ERCC1 gene	ERCC1 expression predictive of tumor response
Cobo et al. [9]	444	Prospective phase III	RT-PCR for ERCC1 mRNA	ERCC1 mRNA levels can be used to customize therapy in the clinical setting